x

Search for a networks

* (*) mandatory field

A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine (Coordination)

  • Type of network : Multinational clinical trials
  • Geographic coverage : Global
  • Funding body(ies) : ONCONOVA THERAPEUTICS, INC 
  • Sponsor : De paz arias
  • Website
  • Coordinator of multinational clinical trial

  • Dr Raquel DE PAZ ARIAS
  • Servicio de Hematología y Hemoterapia
  • Hospital Universitario La Paz
  • Paseo de la Castellana, 261
  • 28046 MADRID
  • SPAIN
  • More information
  • Phone  : 34 917277000
  • Fax  : -
  • Website
Last update: May 2017

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.